HER2 is overexpressed in approximately 10–20% of patients with gastric cancer, and the presence or absence of HER2 positivity affects the recommended regimens in the clinical management of patients with unresectable advanced or recurrent gastric cancer [2, 15]. This evidence concerns the gene ERBB2 and gastric cancer.